ValuEngine upgraded shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a buy rating in a research report report published on Wednesday, June 20th.
CLBS has been the topic of a number of other research reports. HC Wainwright reissued a buy rating and set a $12.00 price target on shares of Caladrius Biosciences in a research note on Wednesday, March 14th. Zacks Investment Research lowered Caladrius Biosciences from a hold rating to a sell rating in a research report on Friday, April 6th. Finally, Chardan Capital raised their price objective on Caladrius Biosciences from $6.50 to $7.00 and gave the company a buy rating in a research report on Friday, March 23rd.
CLBS opened at $6.47 on Wednesday. The company has a market capitalization of $64.21 million, a P/E ratio of -3.63 and a beta of 1.20. Caladrius Biosciences has a 1-year low of $2.63 and a 1-year high of $11.65.
Caladrius Biosciences (NASDAQ:CLBS) last announced its earnings results on Thursday, May 10th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.28. analysts expect that Caladrius Biosciences will post -2.3 earnings per share for the current year.
Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in Caladrius Biosciences in the first quarter worth about $110,000. Macquarie Group Ltd. grew its stake in Caladrius Biosciences by 321.0% in the fourth quarter. Macquarie Group Ltd. now owns 29,890 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 22,790 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Caladrius Biosciences in the first quarter valued at approximately $197,000. Institutional investors and hedge funds own 7.80% of the company’s stock.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.